| ǥ :
|
ȣ - 520424 182 |
| Triple versus Dual Antiplatelet Therapy in Patients with Acute Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention |
| 고려대학교 구로병원 순환기내과¹ 전남대학교병원 순환기내과² |
| Kang-Yin Chen, 나승운, Yong-Jian Li, Kanhaiya L. Poddar, Zhe Jin, Yoshiyasu Minami, 박재형, 나진오, 최철웅, 임홍의, 김진원, 김응주, 박창규, 서홍석, 오동주, 안영근* 정명호 |
Background: Whether the triple antiplatelet therapy is superior or similar to the dual antiplatelet therapy in patients (pts) with acute non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI) is still unclear.
Methods: A total of 1,700 NSTEMI pts undergoing PCI received either dual antiplatelets (aspirin plus clopidogrel, Dual group, n=1,075) or triple antiplatelets (aspirin plus clopidogrel plus cilostazol, Triple group, n=625) therapy.patients in Triple group received additional cilostazol for 1 month, then, changed to receive dual antiplatelet therapy.
Results: The baseline characteristics were similar between these two groups.Events were compared in hospital,1 month and 6 month period.
Conclusions: Despite numerically lower incidences of early revascularization and MACE, the triple antiplatelet therapy appears to be similar to the dual antiplatelet therapy in the pts with NSTEMI undergoing PCI.
|
|
Table: Clinical outcomes of the Study Population
|
Variables, n (%) |
Dual group
(n=1,075 pts) |
Triple group
(n=625 pts) |
P value |
|
In-hospital |
|
|
|
|
Total death |
18 (1.7) |
8 (1.3) |
0.523 |
|
Revascularization |
18 (1.7) |
2 (0.3) |
0.013 |
|
All MACE |
38 (3.5) |
13 (2.1) |
0.090 |
|
TIMI-major bleeding events |
1 (0.1) |
1 (0.2) |
1.000 |
|
At 1 month |
|
|
|
|
Total death |
20 (1.9) |
12 (1.9) |
0.939 |
|
Revascularization |
32 (3.0) |
8 (1.3) |
0.025 |
|
All MACE |
60 (5.7) |
23 (3.7) |
0.076 |
|
At 8 months |
|
|
|
|
Total death |
26 (2.5) |
18 (2.9) |
0.562 |
|
Revascularization |
55 (5.2) |
22 (3.6) |
0.127 |
|
All MACE |
93 (8.8) |
45 (7.3) |
0.292 |
|
|
|
